/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

XILIO THERAPEUTICS, INC. Share Price Today: Live Updates & Key Insights

XILIO THERAPEUTICS, INC. share price today is $0.4809, up -5.31%. The stock opened at $0.5 against the previous close of $0.54, with an intraday high of $0.5301 and low of $0.48.

XILIO THERAPEUTICS, INC. Share Price Chart

style
pb-0

XILIO THERAPEUTICS, INC.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

XILIO THERAPEUTICS, INC. Share Price Performance

$0.4809 -0.0531(-5.31%) XLO at 13 Mar 2026 03:57 PM Biotechnology
Lowest Today 0.48
Highest Today 0.5301
Today’s Open 0.5
Prev. Close 0.54
52 Week High 1.18
52 Week Low 0.46
Day’s Range: Low 0.48 High 0.5301
52-Week Range: Low 0.46 High 1.18
1 day return -
1 Week return -3.69
1 month return -11.93
3 month return -21.31
6 month return -31.79
1 year return -36.05
3 year return -82.6
5 year return -96.81
10 year return -

XILIO THERAPEUTICS, INC. Institutional Holdings

Bain Capital Life Sciences Investors, LLC 10.04

Frazier Life Sciences Management, L.P. 8.05

StemPoint Capital LP 2.76

Merck & Co Inc 2.02

Takeda Pharmaceutical Co Ltd 2.01

Vanguard Group Inc 1.71

Morgan Stanley - Brokerage Accounts 1.31

Vanguard Total Stock Mkt Idx Inv 0.99

AJU IB Investment Co Ltd 0.91

FMR Inc 0.70

Vanguard Institutional Extnd Mkt Idx Tr 0.50

Renaissance Technologies Corp 0.47

Geode Capital Management, LLC 0.45

State Street Corp 0.22

GSA Capital Partners LLP 0.20

Fidelity Extended Market Index 0.19

Stonepine Capital Management Llc 0.17

XTX Topco Ltd 0.10

Northern Trust Corp 0.09

Fidelity Total Market Index 0.09

Two Sigma Investments LLC 0.08

Bridgeway Capital Management, LLC 0.08

Bridgeway Ultra-Small Company Market 0.08

Fidelity Series Total Market Index 0.07

Spartan Extended Market Index Pool F 0.05

NT Ext Equity Mkt Idx Fd - NL 0.05

Vanguard Instl Ttl Stck Mkt Idx Tr 0.05

TWO SIGMA SECURITIES, LLC 0.04

HRT FINANCIAL LLC 0.04

Northern Trust Extended Eq Market Idx 0.04

NT Ext Equity Mkt Idx Fd - L 0.04

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.04

Spartan Total Market Index Pool G 0.03

Fidelity Nasdaq Composite Index 0.02

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

State St US Extended Mkt Indx NL Cl C 0.00

Vanguard U.S. Eq Idx £ Acc 0.00

SSgA U.S. Total Market Index Strategy 0.00

Northern Trust Wilshire 5000 0.00

NT US Market Cap Idx Fd - L 0.00

XILIO THERAPEUTICS, INC. Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

XILIO THERAPEUTICS, INC. Fundamentals

Market Cap 39.67 M

PB Ratio 5.2438

PE Ratio 0.0

Enterprise Value -56.83 M

Total Assets 71.08 M

Volume 1383186

XILIO THERAPEUTICS, INC. Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-81215000 -81.2M, FY22:-87295000 -87.3M, FY21:-74301000 -74.3M, FY20:-55219000 -55.2M, FY19:-17311000 -17.3M

Quarterly Revenue Q3/2025:19066000 19.1M, Q2/2025:8084000 8.1M, Q1/2025:2930000 2.9M, Q3/2024:2263000 2.3M, Q2/2024:2357000 2.4M

Quarterly Profit Q3/2025:18726000 18.7M, Q2/2025:-7246000 -7.2M, Q1/2025:2930000 2.9M, Q3/2024:2263000 2.3M, Q2/2024:1912000 1.9M

Quarterly Net worth Q3/2025:-16286999 -16.3M, Q2/2025:-15844000 -15.8M, Q1/2025:-13265000 -13.3M, Q3/2024:-14020000 -14.0M, Q2/2024:-13925000 -13.9M

About XILIO THERAPEUTICS, INC. & investment objective

Company Information Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Organisation Biotechnology

Employees 64

Industry Biotechnology

CEO Dr. Rene Russo BCPS, Pharm.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow